A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer - Trial NCT06363552
Access comprehensive clinical trial information for NCT06363552 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tianshu Liu and is currently Not yet recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tianshu Liu
Shanghai Zhongshan Hospital
Timeline & Enrollment
Phase 2
May 01, 2024
Dec 01, 2025
Primary Outcome
Objective Response Rate,Incidence and Severity of Dose Limiting Toxicities (DLTs)
Summary
The goal of this clinical trial is to evaluate the preliminary safety and efficacy of SC0191
 as single agent or in combination with bevacizumab or 5-FU/LV in advanced colorectal cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06363552
Non-Device Trial